Does Intrathecal Hydromorphone Cause Constipation?
Yes, intrathecal hydromorphone causes constipation, though the mechanism differs from systemic opioid administration. While intrathecal opioids bypass first-pass metabolism and achieve analgesia at much lower doses, they still bind to peripheral μ-opioid receptors in the enteric nervous system after systemic redistribution, producing the same constellation of gastrointestinal effects—including constipation—that persist without tolerance development.
Mechanism of Constipation with Intrathecal Opioids
Intrathecal hydromorphone causes constipation through two pathways:
Systemic redistribution: After intrathecal administration, hydromorphone undergoes vascular uptake and systemic redistribution, allowing it to reach peripheral μ-opioid receptors in the gut wall 1.
Peripheral receptor binding: Opioids bind to μ-, δ-, and κ-opioid receptors in the enteric nervous system, directly inhibiting peristalsis, reducing mucosal secretions, increasing fluid absorption, and impairing anal sphincter function 1.
Persistent effects without tolerance: Patients rarely develop tolerance to opioid-induced constipation, unlike analgesic effects where tolerance is common; these GI effects continue as long as opioid therapy is maintained 1.
Comparative Constipation Risk Among Opioids
Hydromorphone appears to cause more constipation than some alternative opioids:
Research indicates a relationship between opioid type and degree of constipation, with transdermal fentanyl or methadone tending to cause less constipation compared to morphine or hydromorphone 2.
In a cross-sectional study of 180 patients on long-term opioid therapy, treatment with fentanyl and the interaction between morphine equivalent dose and hydromorphone were associated with more severe constipation 3.
Transdermal fentanyl has experimental and clinical evidence showing less constipation than morphine 4.
Intrathecal Route Does Not Eliminate Constipation Risk
The intrathecal route reduces but does not eliminate systemic opioid exposure:
Spinal (epidural or intrathecal) administration of opioid analgesics should be considered in patients who derive inadequate analgesia or suffer intolerable adverse effects despite optimal use of systemic opioids 4.
The route of administration of morphine—oral versus subcutaneous—does not appear to affect the incidence of opioid-induced constipation 2, suggesting that intrathecal administration similarly will not prevent this adverse effect.
Hydromorphone's metabolite may lead to opioid neurotoxicity, including myoclonus, hyperalgesia, and seizures, and may be more neurotoxic than morphine's metabolite 4.
Clinical Implications and Management
Prophylactic laxative therapy is mandatory from the first dose:
Up to 80–95% of patients receiving opioids develop constipation, and tolerance to this adverse effect does not develop 5.
Initiate a stimulant laxative (senna 2 tablets each morning or bisacodyl 5–15 mg daily) simultaneously with the first opioid dose, including intrathecal hydromorphone 5.
The therapeutic target is one soft, non-forced bowel movement every 1–2 days without straining 5.
Opioid-induced constipation affects 40–80% of patients taking chronic opioid therapy and increases annual healthcare costs by $4,000 per patient 1.
Common Pitfalls to Avoid
Do not assume intrathecal administration prevents constipation: The systemic redistribution of intrathecal opioids still allows peripheral receptor binding in the gut 1.
Do not delay prophylactic laxatives: They must start with the first opioid dose, regardless of route of administration 5.
Do not rely on stool softeners alone: Docusate provides no additional benefit beyond stimulant laxatives and is ineffective for opioid-induced constipation 5.
Consider opioid rotation: If constipation becomes refractory, rotation to intrathecal fentanyl may reduce constipating effects, as fentanyl is associated with less constipation than hydromorphone 4, 6, 2.